Outcome of Uncommon EGFR Mutation Positive Newly Diagnosed Advanced Non-Small Cell Lung Cancer Patients: A Single Center Retrospective Analysis

Lung Cancer: Targets and Therapy - New Zealand
doi 10.2147/lctt.s181406
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Informa UK Limited

Related search

P1.01-44 Outcome of Uncommon EGFR Mutation Positive Newly Diagnosed Advanced NSCLC Patients: A Single-Centre Retrospective Analysis

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Cost‐Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR‐Mutation‐Positive Non‐Small Cell Lung Cancer

Oncologist
Cancer ResearchMedicineOncology
2018English

Clinical Outcome of Treatment of Metastatic Non-Small Cell Lung Cancer in Patients Harboring Uncommon EGFR Mutation

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

Ce4 - Cost-Effectiveness Analysis of First-Line Osimertinib in Patients With Egfr Mutation-Positive Non-Small Cell Lung Cancer

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

P2.03-007 Loxoprofen Prevents EGFR-TKI-Related Skin Rash in Non-Small Cell Lung Cancer Patients: A Single-Center Retrospective Study

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2017English

JCES 01.18 Uncommon Mutation Types of EGFR and Response to EGFR Tyrosine Kinase Inhibitors in Chinese Non-Small Cell Lung Cancer Patients

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2017English

P2.01-29 Economic Analysis of Osimertinib in Previously Untreated EGFR-Positive Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P2.11-09 Uncommon EGFR Mutation Analysis From Urine of Lung Cancer Patients

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Effects of Antacids on Clinical Efficacy of Gefitinib in Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer

Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy